T2 Biosystems (NASDAQ:TTOO) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a report released on Sunday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

T2 Biosystems Trading Up 2.5 %

Shares of TTOO stock opened at $0.41 on Friday. T2 Biosystems has a 12 month low of $0.31 and a 12 month high of $6.95. The business’s 50 day moving average is $0.53 and its two-hundred day moving average is $2.48.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in T2 Biosystems stock. Armistice Capital LLC acquired a new position in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned 9.49% of T2 Biosystems as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 23.18% of the company’s stock.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.